The Effect of Comorbidity on the Use of Adjuvant Chemotherapy and Survival from Colon Cancer: a Retrospective Cohort Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2009 Apr 22

PMID 19379520

Citations 50

Authors

Diana Sarfati

Sarah Hill

Tony Blakely

Bridget Robson

Gordon Purdie

Elizabeth Dennett

Donna Cormack

Kevin Dew

Affiliations

Soon will be listed here.

Abstract

Background: Comorbidity has a well documented detrimental effect on cancer survival. However it is difficult to disentangle the direct effects of comorbidity on survival from indirect effects via the influence of comorbidity on treatment choice. This study aimed to assess the impact of comorbidity on colon cancer patient survival, the effect of comorbidity on treatment choices for these patients, and the impact of this on survival among those with comorbidity.

Methods: This retrospective cohort study reviewed 589 New Zealanders diagnosed with colon cancer in 1996-2003, followed until the end of 2005. Clinical and outcome data were obtained from clinical records and the national mortality database. Cox proportional hazards and logistic regression models were used to assess the impact of comorbidity on cancer specific and all-cause survival, the effect of comorbidity on chemotherapy recommendations for stage III patients, and the impact of this on survival among those with comorbidity.

Results: After adjusting for age, sex, ethnicity, area deprivation, smoking, stage, grade and site of disease, higher Charlson comorbidity score was associated with poorer all-cause survival (HR = 2.63 95%CI:1.82-3.81 for Charlson score > or = 3 compared with 0). Comorbidity count and several individual conditions were significantly related to poorer all-cause survival. A similar, but less marked effect was seen for cancer specific survival. Among patients with stage III colon cancer, those with a Charlson score > or = 3 compared with 0 were less likely to be offered chemotherapy (19% compared with 84%) despite such therapy being associated with around a 60% reduction in excess mortality for both all-cause and cancer specific survival in these patients.

Conclusion: Comorbidity impacts on colon cancer survival thorough both physiological burden of disease and its impact on treatment choices. Some patients with comorbidity may forego chemotherapy unnecessarily, increasing avoidable cancer mortality.

Citing Articles

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data.

Michiels S, Tricas-Sauras S, Salaroli A, Bron D, Lewalle P, Vanschoenbeek K Patient Prefer Adherence. 2024; 18:1991-2006.

PMID: 39345760 PMC: 11439344. DOI: 10.2147/PPA.S472478.

Pan-cancer analyses of the associations between 109 pre-existing conditions and cancer treatment patterns across 19 adult cancers.

Chang W, Lai A Sci Rep. 2024; 14(1):464.

PMID: 38172343 PMC: 10764847. DOI: 10.1038/s41598-024-51161-0.

Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.

Umashankar S, Basu A, Esserman L, Veer L, Melisko M Cancer Med. 2023; 12(22):20906-20917.

PMID: 37902219 PMC: 10709717. DOI: 10.1002/cam4.6632.

Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.

Benderra M, Serrano A, Paillaud E, Tapia C, Cudennec T, Chouaid C ESMO Open. 2023; 8(5):101831.

PMID: 37832389 PMC: 10594025. DOI: 10.1016/j.esmoop.2023.101831.

Comorbidity Patterns in Patients Newly Diagnosed With Colorectal Cancer: Network-Based Study.

Qiu H, Wang L, Zhou L, Wang X JMIR Public Health Surveill. 2023; 9:e41999.

PMID: 37669093 PMC: 10509734. DOI: 10.2196/41999.

References

Polednak A . Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. Cancer Detect Prev. 2006; 30(5):466-72. DOI: 10.1016/j.cdp.2006.07.003. View

Wolmark N, Rockette H, Fisher B, Wickerham D, Redmond C, Fisher E . The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993; 11(10):1879-87. DOI: 10.1200/JCO.1993.11.10.1879. View

Tammemagi C, Neslund-Dudas C, Simoff M, Kvale P . In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol. 2004; 57(6):597-609. DOI: 10.1016/j.jclinepi.2003.11.002. View

Newschaffer C, Penberthy L, Desch C, Retchin S, Whittemore M . The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med. 1996; 156(1):85-90. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Read W, Tierney R, Page N, Costas I, Govindan R, Spitznagel E . Differential prognostic impact of comorbidity. J Clin Oncol. 2004; 22(15):3099-103. DOI: 10.1200/JCO.2004.08.040. View

Schrijvers C, Coebergh J, van der Heijden L, Mackenbach J . Socioeconomic variation in cancer survival in the southeastern Netherlands, 1980-1989. Cancer. 1995; 75(12):2946-53. DOI: 10.1002/1097-0142(19950615)75:12<2946::aid-cncr2820751223>3.0.co;2-6. View

Yancik R, Wesley M, Ries L, Havlik R, Long S, Edwards B . Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998; 82(11):2123-34. View

Salmond C, Crampton P, SUTTON F . NZDep91: A New Zealand index of deprivation. Aust N Z J Public Health. 1999; 22(7):835-7. DOI: 10.1111/j.1467-842x.1998.tb01505.x. View

10.

Tammemagi C, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D . Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294(14):1765-72. DOI: 10.1001/jama.294.14.1765. View

11.

Malenka D, McLerran D, Roos N, Fisher E, WENNBERG J . Using administrative data to describe casemix: a comparison with the medical record. J Clin Epidemiol. 1994; 47(9):1027-32. DOI: 10.1016/0895-4356(94)90118-x. View

12.

Cronin D, Harlan L, Potosky A, Clegg L, Stevens J, Mooney M . Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006; 101(10):2308-18. DOI: 10.1111/j.1572-0241.2006.00775.x. View

13.

Sargent D, Goldberg R, JACOBSON S, Macdonald J, Labianca R, Haller D . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345(15):1091-7. DOI: 10.1056/NEJMoa010957. View

14.

Oconnell M, Mailliard J, Kahn M, Macdonald J, Haller D, Mayer R . Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997; 15(1):246-50. DOI: 10.1200/JCO.1997.15.1.246. View

15.

de Groot V, Beckerman H, Lankhorst G, Bouter L . How to measure comorbidity. a critical review of available methods. J Clin Epidemiol. 2003; 56(3):221-9. DOI: 10.1016/s0895-4356(02)00585-1. View

16.

Kutner J, Vu K, Prindiville S, Byers T . Patient age and cancer treatment decisions. Patient and physician views. Cancer Pract. 2002; 8(3):114-9. DOI: 10.1046/j.1523-5394.2000.83004.x. View

17.

. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264(11):1444-50. View

18.

Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat M, Daures J . A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer. 2005; 93(10):1098-105. PMC: 2361505. DOI: 10.1038/sj.bjc.6602836. View

19.

Gross C, Guo Z, McAvay G, Allore H, Young M, Tinetti M . Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc. 2007; 54(12):1898-904. DOI: 10.1111/j.1532-5415.2006.00973.x. View

20.

Velanovich V, Gabel M, Walker E, Doyle T, OBryan R, Szymanski W . Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients. J Am Coll Surg. 2002; 194(1):8-13. DOI: 10.1016/s1072-7515(01)01132-2. View